查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750663

全球 COPD 和氣喘治療市場：市場規模、佔有率、趨勢分析（按藥品類別、設備/產品、技術/軟體、適應症​​、分銷管道和地區）、細分市場預測（2025-2030 年）

COPD And Asthma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class, By Device/Product, By Technology/Software, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

COPD 和氣喘治療的市場趨勢：

預計 2024 年全球 COPD 和氣喘治療市場規模將達到 923 億美元，2025 年至 2030 年的複合年成長率將達到 9.18%。

污染水平上升、菸草消費和人口老化加劇了慢性呼吸系統疾病的盛行率，大大增加了對支氣管擴張劑、皮質類固醇和聯合治療的需求。

例如，根據全球氣喘防治創議（GINA）預測，2022年全球氣喘患者將超過2.62億，世界衛生組織報告慢性阻塞性肺病（COPD）是全球第三大死因。此外，人口老化以及汽車和工業廢氣排放的增加是全球COPD和氣喘治療產業發展的主要驅動力。工業區附近空氣品質惡化導致氣喘盛行率上升。歐洲環境署表示，2021年的空氣污染物水準大大超過了世界衛生組織（WHO）空氣品質指南規定的水準。達到這些建議水準可防止歐盟成員國（EU-27）出現大量死亡，包括與接觸細懸浮微粒（PM2.5）有關的253,000例死亡和與接觸二氧化氮（NO2）有關的52,000例死亡。此外，減少短期接觸臭氧（O3）可減少22,000例死亡。

慢性阻塞性肺病 (COPD) 和氣喘治療市場也受到藥物輸送設備技術進步的推動，例如藍牙智慧吸入器和基於人工智慧的呼吸監測平台，這些設備提高了治療依從性，並實現了遠端系統管理。 Propeller Health 和 Teva 等公司已經推出了經 FDA核准的智慧吸入器，可以追蹤藥物使用並即時將數據傳輸給臨床醫生。

此外，行動醫療應用程式和遠距呼吸解決方案日益普及，改善了醫療服務的可近性，尤其是在醫療資源匱乏的地區。線上藥局和直銷數位平台的擴張也簡化了治療途徑，支持向居家疾病管理的轉變。綜合來看，這些藥物類別、給藥設備和數位工具的進步預計將使慢性阻塞性肺病和氣喘市場在2030年之前保持持續成長。

醫療成本的上漲、發展中地區醫療服務可近性的改善以及政府旨在管理慢性呼吸系統疾病的支持政策進一步推動了市場潛力。印度和中國等國家全民健保體系的興起，正在擴大基本吸入器和診斷設備的可近性。例如，中國的「健康中國2030」舉措著重於四大戰略支柱：公平獲取醫療服務及取得成果、醫療體系轉型、技術與創新以及環境與氣候永續性。公平是指導減少醫療體系障礙、改善全國健康狀況的根本目標。

新冠疫情對慢性阻塞性肺病 (COPD) 和氣喘治療產業產生了積極影響。起初，由於醫療服務中斷、肺功能檢測減少以及診斷延誤，治療率和處方量有所下降。然而，隨著疫情的進展，人們對呼吸系統健康的認知不斷提高，以及慢性肺病患者出現嚴重後果的風險不斷增加，維持治療的依從性也隨之提高。向居家醫療、遠端醫療以及智慧吸入器和遠端監控等數位健康工具的轉變，為持續治療和患者參與提供了支持。儘管市場面臨短期挫折，但疫情最終強化了主動呼吸系統照護的重要性，並帶來了長期成長機會。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章 市場促進因素、趨勢與範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
    • 產業機會分析
    • 產業挑戰分析
    • 案例研究
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTEL分析
  • COVID-19影響分析

第4章 COPD 和氣喘治療市場：藥物類別估計和趨勢分析

  • 藥品類別細分儀表板
  • 2024 年及 2030 年藥物類別市場佔有率變化分析
  • 2018-2030 年藥品類別市場規模、預測及趨勢分析
    • 支氣管擴張劑
    • 皮質類固醇
    • 白三烯調節劑
    • 抗 IgE/抗 IL 單株抗體
    • 聯合治療
    • 其他

第5章 COPD 和氣喘治療市場：按設備/產品的估計和趨勢分析

  • 設備/產品儀表板
  • 按設備/產品分類的市場佔有率和變化分析（2024 年和 2030 年）
  • 按設備/產品分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 吸入器
    • 吸入器市場（2018-2030）
  • 噴霧器
    • 霧化器市場（2018-2030）
  • 氧氣療法儀
    • 氧氣療法設備市場（2018-2030）

6. 慢性阻塞性肺病和氣喘治療市場：依技術/軟體的估計和趨勢分析

  • 技術/軟體儀錶板
  • 按技術/軟體分類的市場佔有率和變化分析（2024 年和 2030 年）
  • 按技術/軟體分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 藍牙連接智慧吸入器
    • 藍牙智慧吸入器市場（2018-2030）
  • 基於人工智慧的呼吸監測平台
    • 基於人工智慧的呼吸監測平台市場（2018-2030）
  • 症狀追蹤行動應用程式
    • 症狀追蹤行動應用市場（2018-2030）
  • 數位化合規與提醒系統
    • 數位合規與提醒系統市場（2018-2030）
  • 遠端肺部疾病解決方案
    • 遠距肺部疾病解決方案市場（2018-2030）

第7章 COPD 和氣喘治療市場：按適應症的估計和趨勢分析

  • 指示儀表板
  • 市場佔有率和趨勢分析（按適應症分類）（2024 年和 2030 年）
  • 市場規模、預測與趨勢分析（2018-2030 年）
  • 氣喘
    • 氣喘市場（2018-2030）
  • COPD
    • 慢性阻塞性肺病市場（2018-2030）

第 8 章：慢性阻塞性肺病和氣喘治療市場：按分銷管道進行的估計和趨勢分析

  • 按分銷管道分類的儀表板
  • 按分銷管道分類的市場佔有率及變化分析（2024 年及 2030 年）
  • 按分銷管道分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院藥房
    • 醫院藥局市場（2018-2030）
  • 零售藥局
    • 零售藥局市場（2018-2030）
  • 網路藥局
    • 藥局市場（2018-2030）

第9章 COPD 和氣喘治療市場：按地區分類的估計和趨勢分析

  • 區域市場儀表板
  • 區域市場：關鍵要點
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章 競爭格局

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Teva Pharmaceutical Industries Ltd.
    • GSK plc
    • Merck &Co., Inc.
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • Sanofi
    • Koninklijke Philips NV
    • BD
    • Covis Pharma
    • Findair Sp. z oo
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Cipla Ltd.
    • Chiesi Air
Product Code: GVR-4-68040-589-7

COPD & Asthma Therapeutics Market Trends:

The global COPD and asthma therapeutics market size was valued at USD 92.30 billion in 2024 and is expected to grow at a CAGR of 9.18% from 2025 to 2030. The increasing prevalence of chronic respiratory conditions, exacerbated by rising pollution levels, tobacco consumption, and aging populations, is significantly boosting demand for bronchodilators, corticosteroids, and combination therapies.

For instance, according to the Global Initiative for Asthma (GINA), asthma affected over 262 million people globally in 2022, while the WHO reported that COPD was the third leading cause of death worldwide. In addition, a growing aging population coupled with increasing automotive and industrial exhaust gases remains the key driver for the global COPD and asthma therapeutics industry. Degrading air quality near industrial areas has led to an increased incidence of asthma. According to the European Environment Agency, air pollutant levels in 2021 significantly exceeded the levels specified by the World Health Organization's (WHO) air quality guidelines. Achieving these recommended levels could have prevented a significant number of deaths across EU Member States (EU-27), including 253,000 deaths linked to exposure to fine particulate matter (PM2.5) and 52,000 deaths caused by nitrogen dioxide (NO2) exposure. In addition, reducing short-term exposure to ozone (O3) could have reduced 22,000 attributable deaths.

The COPD and asthma therapeutics market is also propelled by technological advancements in drug delivery devices, such as smart inhalers with Bluetooth connectivity and AI-based respiratory monitoring platforms, which enhance treatment adherence and enable remote patient management. Companies like Propeller Health and Teva have introduced FDA-approved smart inhalers that track medication usage and transmit data to clinicians in real time.

Moreover, the growing penetration of mobile health apps and telepulmonology solutions is improving access to care, especially in underserved areas. The expansion of online pharmacies and direct-to-consumer digital platforms is also streamlining therapy access, supporting the shift towards home-based disease management. Collectively, these advancements across therapeutic classes, delivery devices, and digital tools are expected to drive sustained growth in the COPD and asthma market through 2030.

Increasing healthcare expenditure, improved access to care in developing regions, and supportive government initiatives aimed at managing chronic respiratory conditions are further enhancing market potential. The rise of universal healthcare programs in countries such as India and China is expanding access to essential inhalers and diagnostics. For instance, China's Healthy China 2030 initiative focuses on four strategic pillars: equitable access and outcomes in health and healthcare, healthcare systems transformation, technology and innovation, and environmental and climate sustainability. Equity is the foundational goal, guiding efforts to reduce barriers in healthcare systems and improve health outcomes across the country.

The COVID-19 pandemic positively impacted the COPD and asthma therapeutics industry. Initially, disruptions in healthcare access, reduced pulmonary function testing, and delayed diagnoses led to a decline in treatment rates and prescription volumes. However, as the pandemic progressed, heightened awareness of respiratory health and the increased risk of severe COVID-19 outcomes in patients with chronic lung diseases drove greater adherence to maintenance therapies. The shift toward home-based care, telemedicine, and digital health tools, such as smart inhalers and remote monitoring, supported continued treatment and patient engagement. While the market faced short-term setbacks, the pandemic ultimately reinforced the importance of proactive respiratory care, leading to long-term growth opportunities.

Global COPD And Asthma Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global COPD and asthma therapeutics market report based on drug class, device/product, technology/software, indication, distribution channel, and region:

  • Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
  • Bronchodilators
  • Corticosteroids
  • Leukotriene Modifiers
  • Anti-IgE and Anti-IL Monoclonal Antibodies
  • Combination Therapy
  • Others
  • Device/Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Inhalers
    • Dry Powder Inhalers (DPI)
    • Metered Dose Inhalers (MDI)
    • Soft Mist Inhalers (SMI)
  • Nebulizers
    • Jet
    • Mesh
    • Ultrasonic
  • Oxygen Therapy Devices
  • Technology/Software Outlook (Revenue, USD Million, 2018 - 2030)
  • Smart Inhalers with Bluetooth Connectivity
  • AI-based Respiratory Monitoring Platforms
  • Mobile Apps for Symptom Tracking
  • Digital Adherence and Reminder Systems
  • Telepulmonology Solutions
  • Indication Outlook (Revenue, USD Million, 2018 - 2030)
  • Asthma
  • COPD
  • Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Device/Product
    • 1.2.3. Technology/Software
    • 1.2.4. Indication
    • 1.2.5. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Emergence of novel biologics
      • 3.2.1.2. Growing adoption of AI technologies in diagnostics, remote monitoring, and treatment optimization.
      • 3.2.1.3. Advancements in smart inhalers and digital health tools enhancing patient adherence and outcomes.
      • 3.2.1.4. Strong pipeline of innovative drugs and fixed-dose combination therapies.
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory hurdles and lengthy approval timelines for novel therapeutics.
      • 3.2.2.2. High cost of biologics and advanced therapies
    • 3.2.3. Industry Opportunity Analysis
    • 3.2.4. Industry Challenge Analysis
    • 3.2.5. Case Studies
  • 3.3. Business Environment Analysis
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
  • 3.4. COVID-19 Impact Analysis

Chapter 4. COPD and Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Segment Dashboard
  • 4.2. Drug Class Market Share Movement Analysis, 2024 & 2030
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
    • 4.3.1. Bronchodilators
      • 4.3.1.1. Bronchodilators market, 2018 - 2030 (USD Million)
    • 4.3.2. Corticosteroids
      • 4.3.2.1. Corticosteroids market, 2018 - 2030 (USD Million)
    • 4.3.3. Leukotriene Modifiers
      • 4.3.3.1. Leukotriene Modifiers market, 2018 - 2030 (USD Million)
    • 4.3.4. Anti-IgE and Anti-IL Monoclonal Antibodies
      • 4.3.4.1. Anti-IgE and Anti-IL Monoclonal Antibodies market, 2018 - 2030 (USD Million)
    • 4.3.5. Combination Therapy
      • 4.3.5.1. Combination Therapy market, 2018 - 2030 (USD Million)
    • 4.3.6. Others
      • 4.3.6.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. COPD and Asthma Therapeutics Market: Device/Product Estimates & Trend Analysis

  • 5.1. Device/Product Dashboard
  • 5.2. Device/Product Market Share Movement Analysis, 2024 & 2030
  • 5.3. Market Size & Forecasts and Trend Analysis, by Device/Product, 2018 to 2030 (USD Million)
  • 5.4. Inhalers
    • 5.4.1. Inhalers market, 2018 - 2030 (USD Million)
      • 5.4.1.1. Dry Powder Inhalers
      • 5.4.1.1.1.Dry Powder Inhalers market, 2018 - 2030 (USD Million)
      • 5.4.1.2. Metered Dose Inhalers
      • 5.4.1.2.1.Metered Dose Inhalers market, 2018 - 2030 (USD Million)
      • 5.4.1.3. Soft Mist Inhalers
      • 5.4.1.3.1.Soft Mist Inhalers market, 2018 - 2030 (USD Million)
  • 5.5. Nebulizers
    • 5.5.1. Nebulizers market, 2018 - 2030 (USD Million)
      • 5.5.1.1. Jet nebulizers
        • 5.5.1.1.1. Jet nebulizers market, 2018 - 2030 (USD Million)
      • 5.5.1.2. Mesh nebulizers
        • 5.5.1.2.1. Mesh nebulizers market, 2018 - 2030 (USD Million)
      • 5.5.1.3. Ultrasonic
        • 5.5.1.3.1. Ultrasonic Inhalers market, 2018 - 2030 (USD Million)
  • 5.6. Oxygen Therapy Devices
    • 5.6.1. Oxygen Therapy Devices market, 2018 - 2030 (USD Million)

Chapter 6. COPD and Asthma Therapeutics Market: Technology/Software Estimates & Trend Analysis

  • 6.1. Technology/Software Segment Dashboard
  • 6.2. Technology/Software Market Share Movement Analysis, 2024 & 2030
  • 6.3. Market Size & Forecasts and Trend Analysis, by Technology/Software, 2018 to 2030 (USD Million)
  • 6.4. Smart Inhalers with Bluetooth Connectivity
    • 6.4.1. Smart Inhalers with Bluetooth Connectivity market, 2018 - 2030 (USD Million)
  • 6.5. AI-based Respiratory Monitoring Platforms
    • 6.5.1. AI-based Respiratory Monitoring Platforms market, 2018 - 2030 (USD Million)
  • 6.6. Mobile Apps for Symptom Tracking
    • 6.6.1. Mobile Apps for Symptom Tracking market, 2018 - 2030 (USD Million)
  • 6.7. Digital Adherence and Reminder Systems
    • 6.7.1. Digital Adherence and Reminder Systems market, 2018 - 2030 (USD Million)
  • 6.8. Telepulmonology Solutions
    • 6.8.1. Telepulmonology Solutions market, 2018 - 2030 (USD Million)

Chapter 7. COPD and Asthma Therapeutics Market: Indication Estimates & Trend Analysis

  • 7.1. Indication Segment Dashboard
  • 7.2. Indication Market Share Movement Analysis, 2024 & 2030
  • 7.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 7.4. Asthma
    • 7.4.1. Asthma market, 2018 - 2030 (USD Million)
  • 7.5. COPD
    • 7.5.1. COPD market, 2018 - 2030 (USD Million)

Chapter 8. COPD and Asthma Therapeutics Market: Distribution Channel Estimates & Trend Analysis

  • 8.1. Distribution Channel Segment Dashboard
  • 8.2. Distribution Channel Market Share Movement Analysis, 2024 & 2030
  • 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 8.4. Hospital Pharmacies
    • 8.4.1. Hospital Pharmacies market, 2018 - 2030 (USD Million)
  • 8.5. Retail Pharmacies
    • 8.5.1. Retail Pharmacies market, 2018 - 2030 (USD Million)
  • 8.6. Online Pharmacies
    • 8.6.1. Drug Stores market, 2018 - 2030 (USD Million)

Chapter 9. COPD and Asthma Therapeutics Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Dashboard
  • 9.2. Regional Market: Key Takeaways
  • 9.3. North America
    • 9.3.1. North America COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.2. U.S.
      • 9.3.2.1. Key country dynamic
      • 9.3.2.2. Regulatory framework
      • 9.3.2.3. Competitive insights
      • 9.3.2.4. U.S. COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.3. Canada
      • 9.3.3.1. Key country dynamic
      • 9.3.3.2. Regulatory framework
      • 9.3.3.3. Competitive insights
      • 9.3.3.4. Canada COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.4. Mexico
      • 9.3.4.1. Key country dynamic
      • 9.3.4.2. Regulatory framework
      • 9.3.4.3. Competitive insights
      • 9.3.4.4. Mexico COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4. Europe
    • 9.4.1. Europe COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. Germany
      • 9.4.2.1. Key country dynamic
      • 9.4.2.2. Regulatory framework
      • 9.4.2.3. Competitive insights
      • 9.4.2.4. Germany COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. UK
      • 9.4.3.1. Key country dynamic
      • 9.4.3.2. Regulatory framework
      • 9.4.3.3. Competitive insights
      • 9.4.3.4. UK COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. France
      • 9.4.4.1. Key country dynamic
      • 9.4.4.2. Regulatory framework
      • 9.4.4.3. Competitive insights
      • 9.4.4.4. France COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.5. Italy
      • 9.4.5.1. Key country dynamic
      • 9.4.5.2. Regulatory framework
      • 9.4.5.3. Competitive insights
      • 9.4.5.4. Italy COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.6. Spain
      • 9.4.6.1. Key country dynamic
      • 9.4.6.2. Regulatory framework
      • 9.4.6.3. Competitive insights
      • 9.4.6.4. Spain COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.7. Denmark
      • 9.4.7.1. Key country dynamic
      • 9.4.7.2. Regulatory framework
      • 9.4.7.3. Competitive insights
      • 9.4.7.4. Denmark COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.8. Sweden
      • 9.4.8.1. Key country dynamic
      • 9.4.8.2. Regulatory framework
      • 9.4.8.3. Competitive insights
      • 9.4.8.4. Sweden COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.9. Norway
      • 9.4.9.1. Key country dynamic
      • 9.4.9.2. Regulatory framework
      • 9.4.9.3. Competitive insights
      • 9.4.9.4. Norway COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Asia Pacific COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. Japan
      • 9.5.2.1. Key country dynamic
      • 9.5.2.2. Regulatory framework
      • 9.5.2.3. Competitive insights
      • 9.5.2.4. Japan COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. China
      • 9.5.3.1. Key country dynamic
      • 9.5.3.2. Regulatory framework
      • 9.5.3.3. Competitive insights
      • 9.5.3.4. China COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.4. India
      • 9.5.4.1. Key country dynamic
      • 9.5.4.2. Regulatory framework
      • 9.5.4.3. Competitive insights
      • 9.5.4.4. India COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.5. South Korea
      • 9.5.5.1. Key country dynamic
      • 9.5.5.2. Regulatory framework
      • 9.5.5.3. Competitive insights
      • 9.5.5.4. South Korea COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.6. Australia
      • 9.5.6.1. Key country dynamic
      • 9.5.6.2. Regulatory framework
      • 9.5.6.3. Competitive insights
      • 9.5.6.4. Australia COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.7. Thailand
      • 9.5.7.1. Key country dynamic
      • 9.5.7.2. Regulatory framework
      • 9.5.7.3. Competitive insights
      • 9.5.7.4. Thailand COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Latin America COPD and Asthma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. Brazil
      • 9.6.2.1. Key country dynamic
      • 9.6.2.2. Regulatory framework
      • 9.6.2.3. Competitive insights
      • 9.6.2.4. Brazil COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.6.3. Argentina
      • 9.6.3.1. Key country dynamic
      • 9.6.3.2. Regulatory framework
      • 9.6.3.3. Competitive insights
      • 9.6.3.4. Argentina COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7. MEA
    • 9.7.1. MEA COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.2. South Africa
      • 9.7.2.1. Key country dynamic
      • 9.7.2.2. Regulatory framework
      • 9.7.2.3. Competitive insights
      • 9.7.2.4. South Africa COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.3. Saudi Arabia
      • 9.7.3.1. Key country dynamic
      • 9.7.3.2. Regulatory framework
      • 9.7.3.3. Competitive insights
      • 9.7.3.4. Saudi Arabia COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.4. UAE
      • 9.7.4.1. Key country dynamic
      • 9.7.4.2. Regulatory framework
      • 9.7.4.3. Competitive insights
      • 9.7.4.4. UAE COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.5. Kuwait
      • 9.7.5.1. Key country dynamic
      • 9.7.5.2. Regulatory framework
      • 9.7.5.3. Competitive insights
      • 9.7.5.4. Kuwait COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1. Teva Pharmaceutical Industries Ltd.
      • 10.5.1.1. Overview
      • 10.5.1.2. Financial performance
      • 10.5.1.3. Product benchmarking
      • 10.5.1.4. Strategic initiatives
    • 10.5.2. GSK plc
      • 10.5.2.1. Overview
      • 10.5.2.2. Financial performance
      • 10.5.2.3. Product benchmarking
      • 10.5.2.4. Strategic initiatives
    • 10.5.3. Merck & Co., Inc.
      • 10.5.3.1. Overview
      • 10.5.3.2. Financial performance
      • 10.5.3.3. Product benchmarking
      • 10.5.3.4. Strategic initiatives
    • 10.5.4. F. Hoffmann-La Roche Ltd
      • 10.5.4.1. Overview
      • 10.5.4.2. Financial performance
      • 10.5.4.3. Product benchmarking
      • 10.5.4.4. Strategic initiatives
    • 10.5.5. AstraZeneca
      • 10.5.5.1. Overview
      • 10.5.5.2. Financial performance
      • 10.5.5.3. Product benchmarking
      • 10.5.5.4. Strategic initiatives
    • 10.5.6. Boehringer Ingelheim International GmbH
      • 10.5.6.1. Overview
      • 10.5.6.2. Financial performance
      • 10.5.6.3. Product benchmarking
      • 10.5.6.4. Strategic initiatives
    • 10.5.7. Sanofi
      • 10.5.7.1. Overview
      • 10.5.7.2. Financial performance
      • 10.5.7.3. Product benchmarking
      • 10.5.7.4. Strategic initiatives
    • 10.5.8. Koninklijke Philips N.V.
      • 10.5.8.1. Overview
      • 10.5.8.2. Financial performance
      • 10.5.8.3. Product benchmarking
      • 10.5.8.4. Strategic initiatives
    • 10.5.9. BD
      • 10.5.9.1. Overview
      • 10.5.9.2. Financial performance
      • 10.5.9.3. Product benchmarking
    • 10.5.10. Covis Pharma
      • 10.5.10.1. Overview
      • 10.5.10.2. Financial performance
      • 10.5.10.3. Product benchmarking
    • 10.5.11. Findair Sp. z o. o.
      • 10.5.11.1. Overview
      • 10.5.11.2. Financial performance
      • 10.5.11.3. Product benchmarking
    • 10.5.12. Novartis AG
      • 10.5.12.1. Overview
      • 10.5.12.2. Financial performance
      • 10.5.12.3. Product benchmarking
    • 10.5.13. F. Hoffmann-La Roche Ltd
      • 10.5.13.1. Overview
      • 10.5.13.2. Financial performance
      • 10.5.13.3. Product benchmarking
    • 10.5.14. Cipla Ltd.
      • 10.5.14.1. Overview
      • 10.5.14.2. Financial performance
      • 10.5.14.3. Product benchmarking
    • 10.5.15. Chiesi Air
      • 10.5.15.1. Overview
      • 10.5.15.2. Financial performance
      • 10.5.15.3. Product benchmarking

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. North America COPD and asthma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 4. North America COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 5. North America COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 6. North America COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 7. North America COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 8. North America COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 9. U.S. COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 10. U.S. COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 11. U.S. COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 12. U.S. COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 13. U.S. COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 14. Canada COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 15. Canada COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 16. Canada COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 17. Canada COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 18. Canada COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 19. Mexico COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 20. Mexico COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 21. Mexico COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 22. Mexico COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 23. Mexico COPD and asthma therapeutics market, by distribution channel scope, 2018-
  • Table 24. Europe COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 25. Europe COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 26. Europe COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 27. Europe COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 28. Europe COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 29. UK COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 30. UK COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 31. UK COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 32. UK COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 33. UK COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 34. Germany COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 35. Germany COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 36. Germany COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 37. Germany COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 38. Germany COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 39. France COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 40. France COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 41. France COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 42. France COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 43. France COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 44. Italy COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 45. Italy COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 46. Italy COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 47. Italy COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 48. Italy COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 49. Spain COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 50. Spain COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 51. Spain COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 52. Spain COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 53. Spain COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 54. Norway COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 55. Norway COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 56. Norway COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 57. Norway COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 58. Norway COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 59. Sweden COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 60. Sweden COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 61. Sweden COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 62. Sweden COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 63. Sweden COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 64. Denmark COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 65. Denmark COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 66. Denmark COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 67. Denmark COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 68. Denmark COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 69. Asia Pacific COPD and asthma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 70. Asia Pacific COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 71. Asia Pacific COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 72. Asia Pacific COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 73. Asia Pacific COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 74. Asia Pacific COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 75. Japan COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 76. Japan COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 77. Japan COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 78. Japan COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 79. Japan COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 80. China COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 81. China COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 82. China COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 83. China COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 84. China COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 85. India COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 86. India COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 87. India COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 88. India COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 89. India COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 90. Australia COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 91. Australia COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 92. Australia COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 93. Australia COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 94. Australia COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 95. South Korea COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 96. South Korea COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 97. South Korea COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 98. South Korea COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 99. South Korea COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 100. Thailand COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 101. Thailand COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 102. Thailand COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 103. Thailand COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 104. Thailand COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 105. Latin America COPD and asthma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 106. Latin America COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 107. Latin America COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 108. Latin America COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 109. Latin America COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 110. Latin America COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 111. Brazil COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 112. Brazil COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 113. Brazil COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 114. Brazil COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 115. Brazil COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 116. Argentina COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 117. Argentina COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 118. Argentina COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 119. Argentina COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 120. Argentina COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 121. Middle East & Africa COPD and asthma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 122. Middle East & Africa COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 123. Middle East & Africa COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 124. Middle East & Africa COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 125. Middle East & Africa COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 126. Middle East & Africa COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 127. South Africa COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 128. South Africa COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 129. South Africa COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 130. South Africa COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 131. South Africa COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 132. Saudi Arabia COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 133. Saudi Arabia COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 134. Saudi Arabia COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 135. Saudi Arabia COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 136. Saudi Arabia COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 137. UAE COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 138. UAE COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 139. UAE COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 140. UAE COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 141. UAE COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 142. Kuwait COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 143. Kuwait COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 144. Kuwait COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 145. Kuwait COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 146. Kuwait COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 COPD and asthma therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market formulation & validation
  • Fig. 6 Market research approaches
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD modelling for market share assessment
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Market snapshot
  • Fig. 11 Market segmentation (USD Million)
  • Fig. 12 Competitive landscape
  • Fig. 13 Parent market outlook (In USD Billion)
  • Fig. 14 Related/ancillary market outlook (In USD Billion)
  • Fig. 15 COPD and asthma therapeutics market dynamics
  • Fig. 16 COPD and asthma therapeutics market: Porter's five forces analysis
  • Fig. 17 COPD and asthma therapeutics market: PESTLE analysis
  • Fig. 18 COPD and asthma therapeutics market: Drug class segment dashboard
  • Fig. 19 COPD and asthma therapeutics market: Drug class market share analysis, 2024 & 2030
  • Fig. 20 Bronchodilators market, 2018 - 2030 (USD Million)
  • Fig. 21 Corticosteroids market, 2018 - 2030 (USD Million)
  • Fig. 22 Leukotriene Modifiers market, 2018 - 2030 (USD Million)
  • Fig. 23 Anti-IgE and Anti-IL Monoclonal Antibodies market, 2018 - 2030 (USD Million)
  • Fig. 24 Combination Therapy market, 2018 - 2030 (USD Million)
  • Fig. 25 Others market, 2018 - 2030 (USD Million)
  • Fig. 26 COPD and asthma therapeutics market: Device/Product segment dashboard
  • Fig. 27 COPD and asthma therapeutics market: Device/Product market share analysis, 2024 & 2030
  • Fig. 28 Inhalers market, 2018 - 2030 (USD Million)
  • Fig. 29 Nebulizers market, 2018 - 2030 (USD Million)
  • Fig. 30 Oxygen Therapy Devices market, 2018 - 2030 (USD Million)
  • Fig. 31 COPD and asthma therapeutics market: Technology/Software segment dashboard
  • Fig. 32 COPD and asthma therapeutics market: Technology/Software market share analysis, 2024 & 2030
  • Fig. 33 Smart Inhalers with Bluetooth Connectivity market, 2018 - 2030 (USD Million)
  • Fig. 34 AI-based Respiratory Monitoring Platforms market, 2018 - 2030 (USD Million)
  • Fig. 35 Mobile Apps for Symptom Tracking market, 2018 - 2030 (USD Million)
  • Fig. 36 Digital Adherence and Reminder Systems market, 2018 - 2030 (USD Million)
  • Fig. 37 Telepulmonology Solutions and Reminder Systems market, 2018 - 2030 (USD Million)
  • Fig. 38 COPD and asthma therapeutics market: Indication market share analysis, 2024 & 2030
  • Fig. 39 Asthma market, 2018 - 2030 (USD Million)
  • Fig. 40 COPD market, 2018 - 2030 (USD Million
  • Fig. 41 COPD and asthma therapeutics market revenue, by region
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 North America COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 US COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Canada COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Mexico COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 50 Europe COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 UK COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Germany COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 France COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Italy COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Spain COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Norway COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Sweden COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Denmark COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Japan COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 China COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 India COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Australia COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 South Korea COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Thailand COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Brazil COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Argentina COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 85 MEA COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 South Africa COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Saudi Arabia COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 UAE COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Kuwait healthcare information system market, 2018 - 2030 (USD Million)
  • Fig. 94 Company categorization
  • Fig. 95 Company market position analysis
  • Fig. 96 Strategic framework